4月22日 - ** Certara CERT.O早盘股价上涨2.4%至6.35美元
** 这家药物开发软件制造商称， (link) 已达成协议，将其监管和医学写作业务出售给合同药品开发商 Veristat，交易对价最高达 1.35 亿美元。
** 该业务为药物开发提供文件制作服务，确保合规和及时提交文件
** 首席执行官表示："这项交易强调了我们在整个药物开发生命周期加速人工智能集成建模和模拟的承诺
** 2025 年，该业务创造了 5000 万美元的收入和 1700 万美元的调整后核心利润
** CERT 计划更新其 2026 年的预测，以反映交易完成后的此次出售。
** 截至上次收盘，股价年累计下跌 29.6%。
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.